{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:48:06Z","timestamp":1782370086314,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02808-x","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:25:28Z","timestamp":1775208328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practice of radiation therapy for squamous cell esophageal cancer in Austria \u2013 a survey on behalf of the \u00d6GRO-GIT"],"prefix":"10.1186","volume":"21","author":[{"given":"Sabine","family":"Gerum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Salinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Komina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Peterka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schwaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Stranzl-Lawatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Venhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"3","key":"2808_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2808_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. CROSS.","journal-title":"N Engl J Med"},{"key":"2808_CR3","unstructured":"Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16."},{"key":"2808_CR4","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062\u20137.","journal-title":"J Clin Oncol"},{"key":"2808_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392.","journal-title":"Lancet Oncol"},{"issue":"15","key":"2808_CR6","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","volume":"49","author":"U Ronellenfitsch","year":"2013","unstructured":"Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3149\u201358.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2808_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000001905","volume":"265","author":"S Pasquali","year":"2017","unstructured":"Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg. 2017;265(3):481\u201391.","journal-title":"Ann Surg"},{"key":"2808_CR8","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial Lancet Oncol. 2016;17(12):1697\u20131708. Epub 2016 Oct 22.PMID: 27776843.","DOI":"10.1016\/S1470-2045(16)30531-9"},{"key":"2808_CR9","doi-asserted-by":"publisher","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(23)00243-1","DOI":"10.1016\/S2468-1253(23)00243-1"},{"issue":"1","key":"2808_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"issue":"4","key":"2808_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025;392(4):323\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2409408.","journal-title":"N Engl J Med"},{"issue":"6","key":"2808_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bjc.2017.21","volume":"116","author":"T Crosby","year":"2017","unstructured":"Crosby T, Hurt CN, Falk S, et al. Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy \u00fe\/- cetuximab in oesophageal cancer. Br J Cancer. 2017;116(6):709\u201316.","journal-title":"Br J Cancer"},{"issue":"13","key":"2808_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"J Med"},{"key":"2808_CR14","doi-asserted-by":"crossref","unstructured":"Mariette C, Dahan L, Mornex F et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014.","DOI":"10.1200\/JCO.2013.53.6532"},{"issue":"25","key":"2808_CR15","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/JCO.20.03697","volume":"39","author":"M Hulshof","year":"2021","unstructured":"Hulshof M, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECOStudy). J ClinOncol. 2021;39(25):2816\u201324.","journal-title":"J ClinOncol"},{"issue":"10","key":"2808_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004. Epub 2022 Jul 29.","journal-title":"Ann Oncol"},{"key":"2808_CR17","unstructured":"NCCN Clinical Practice. Guidelines in Esophageal and esophagogastric junction cancers, Version 2.2024. https:\/\/www.nccn.org. Assessed Mai 11, 2024."},{"key":"2808_CR18","doi-asserted-by":"publisher","unstructured":"Lu J, Sun DX, Yang X et al. Impact of PET\/CT on radiation treatment in patients with esophageal cancer: A systematic review Crit Rev Oncol Hematol. 2016;107: 128\u2013137. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.015. Epub 2016 Sep 13.","DOI":"10.1016\/j.critrevonc.2016.08.015"},{"key":"2808_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jtcvs.2008.11.016","volume":"137","author":"RJ Cerfolio","year":"2009","unstructured":"Cerfolio RJ, Bryant AS, Talati AA, et al. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J Thorac Cardiovasc Surg. 2009;137:605\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"2808_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ijrobp.2019.12.038","volume":"106","author":"AS Borggreve","year":"2020","unstructured":"Borggreve AS, van Rossum LSN. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET\/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2020;106(5):998\u20131009. 2019.12.038. Epub 2020 Jan 25.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2808_CR21","doi-asserted-by":"publisher","unstructured":"Sakin A, Ozcelik M, Sahin S et al. The prognostic effect of pretreatment 18F-FDG PET\/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy Surg Oncol. 2022;43:101809. https:\/\/doi.org\/10.1016\/j.suronc.2022.101809. Epub 2022 Jul 5.","DOI":"10.1016\/j.suronc.2022.101809"},{"key":"2808_CR22","doi-asserted-by":"publisher","unstructured":"Hegemann NS, Koepple R, Walter F et al. Neoadjuvant chemoradiation for esophageal cancer: Surgery improves locoregional control while response based on FDG-PET\/CT predicts survival Strahlenther Onkol. 2018;194(5):435\u2013443. https:\/\/doi.org\/10.1007\/s00066-018-1261-y. Epub 2018 Jan 18.","DOI":"10.1007\/s00066-018-1261-y"},{"issue":"5","key":"2808_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12149-022-01733-9","volume":"36","author":"M Krengli","year":"2022","unstructured":"Krengli M, Ferrara E, Guaschino R, et al. 18F-FDG PET\/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment. Ann Nucl Med. 2022;36(5):450\u20139. https:\/\/doi.org\/10.1007\/s12149-022-01733-9. Epub 2022 Mar 11.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"2808_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/MNM.0000000000001619","volume":"43","author":"W Zhang","year":"2022","unstructured":"Zhang W, Jia H, Chen Z, et al. The prognostic value of positron emission tomography\/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy. Nucl Med Commun. 2022;43(12):1239\u201346. https:\/\/doi.org\/10.1097\/MNM.0000000000001619. Epub 2022 Oct 19.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"2808_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/MNM.0000000000001168","volume":"41","author":"K Kitajima","year":"2020","unstructured":"Kitajima K, Kaida H, Nakatani K, et al. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan. Nucl Med Commun. 2020;41(5):443\u201351. https:\/\/doi.org\/10.1097\/MNM.0000000000001168.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2808_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.canrad.2016.12.004","volume":"21","author":"J Encaoua","year":"2017","unstructured":"Encaoua J, Abgral R, Leleuc C, et al. Radiotherapy volume delineation based on (18F)-fluorodeoxyglucose positron emission tomography for locally advanced or inoperable. oesophageal cancer Cancer Radiother. 2017;21(4):267\u201375. https:\/\/doi.org\/10.1016\/j.canrad.2016.12.004.","journal-title":"oesophageal cancer Cancer Radiother"},{"key":"2808_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejrad.2014.10.014]","volume":"84","author":"KE Rollins","year":"2015","unstructured":"Rollins KE, Lucas E, Tewari N, et al. PET-CT offers accurate assessment of tumour length in oesophageal malignancy. Eur J Radiol. 2015;84:195\u2013200. https:\/\/doi.org\/10.1016\/j.ejrad.2014.10.014]. [PMID: 25435270.","journal-title":"Eur J Radiol"},{"issue":"5","key":"2808_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3748\/wjg.v23.i5.751","volume":"23","author":"T DaVee","year":"2017","unstructured":"DaVee T, Ajani JA, Lee HJ, et al. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017;23(5):751\u201362. https:\/\/doi.org\/10.3748\/wjg.v23.i5.751.","journal-title":"World J Gastroenterol"},{"key":"2808_CR29","doi-asserted-by":"publisher","unstructured":"Tirumani H, Rosenthal MH, Tirumani SH et al. Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management. Can Assoc Radiol J. 2015;66(2):130\u20139. https:\/\/doi.org\/10.1016\/j.carj.2014.08.006. Epub 2015 Mar 12.","DOI":"10.1016\/j.carj.2014.08.006"},{"key":"2808_CR30","first-page":"1479e90","volume":"14","author":"SR Puli","year":"2008","unstructured":"Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008;14:1479e90.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2808_CR31","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1177\/2050640619856459","volume":"7","author":"S an de Ven","year":"2019","unstructured":"van de Ven S, Bugter O, Hardillo JA, et al. Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: A systematic review and meta-analysis United. Eur Gastroenterol J. 2019;7(10):1304\u201311. https:\/\/doi.org\/10.1177\/2050640619856459.","journal-title":"Eur Gastroenterol J"},{"key":"2808_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0261-5614(03)00098-0","volume":"22","author":"J Kondrup","year":"2003","unstructured":"Kondrup J, Allison SP, Elia M, et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22:415\u201321.","journal-title":"Clin Nutr"},{"issue":"7","key":"2808_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/a-1475-0063","volume":"53","author":"MCW van der Spaander","year":"2021","unstructured":"Spaander MCW, van der Bogt RD, Baron TH, et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE). Guideline \u2013 Update 2021 Endoscopy. 2021;53(7):751\u201362. https:\/\/doi.org\/10.1055\/a-1475-0063. Epub 2021 Apr 30.","journal-title":"Guideline \u2013 Update 2021 Endoscopy"},{"key":"2808_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.gie.2014.06.004","volume":"80","author":"MW n den Berg","year":"2014","unstructured":"van den Berg MW, Walter D, de Vries EM, et al. Biodegradable stent placement before neoadjuvant chemoradiotherapy as a bridge to surgery in patients with locally advanced esophageal cancer. Gastrointest Endosc. 2014;80:908\u201313.","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"2808_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jamcollsurg.2014.11.028","volume":"220","author":"C Mariette","year":"2015","unstructured":"Mariette C, Gronnier C, Duhamel A, et al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. J Am Coll Surg. 2015;220(3):287\u201396. Epub 2014 Dec 12.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"2808_CR36","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1634\/theoncologist.2017-0646","volume":"23","author":"YF Lu","year":"2018","unstructured":"Lu YF, Chung CS, Liu CY, et al. Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not? Oncologist. 2018;23(12):1426\u201335. https:\/\/doi.org\/10.1634\/theoncologist.2017-0646. Epub 2018 May 4.PMID: 29728468.","journal-title":"Oncologist"},{"key":"2808_CR37","doi-asserted-by":"publisher","unstructured":"Oppedijk V, van der Gaast A, van Lanschot JB, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS Trials. J Clin Oncol. 2014;32(5):385\u2009\u2013\u200991. https:\/\/doi.org\/10.1200\/JCO.2013.51.2186. Epub 2014 Jan 13.","DOI":"10.1200\/JCO.2013.51.2186"},{"issue":"18","key":"2808_CR38","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surger for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021;39(18):1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614. Epub 2021 Apr 23.","journal-title":"J Clin Oncol"},{"key":"2808_CR39","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310\u20137.","journal-title":"J Clin Oncol"},{"key":"2808_CR40","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","volume":"25","author":"L Bedenne","year":"2007","unstructured":"Bedenne L, Michel P, Bouch\u00e9 O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160\u20138.","journal-title":"J Clin Oncol"},{"key":"2808_CR41","doi-asserted-by":"crossref","unstructured":"Wang H, Song CH, Zhao X et al. The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer- a systematic review and meta-analysis Front Oncol. 2022. PMID: 36408184.","DOI":"10.3389\/fonc.2022.1034656"},{"issue":"8","key":"2808_CR42","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021;156(8):721\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.2373.","journal-title":"JAMA Surg"},{"issue":"5","key":"2808_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94 \u2013 05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2808_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"M-P Conroy Th, Galais","year":"2014","unstructured":"Conroy Th, Galais M-P, Raoul J-L, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(14)70028-2.","journal-title":"Lancet Oncol"},{"issue":"25","key":"2808_CR45","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.20.03611","volume":"39","author":"KA Goodman","year":"2021","unstructured":"Goodman KA, Ou FS, Hall NC, et al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance. Trial Clin Oncol. 2021;39(25):2803\u201315. https:\/\/doi.org\/10.1200\/JCO.20.03611. Epub 2021 Jun 2.","journal-title":"Trial Clin Oncol"},{"issue":"17","key":"2808_CR46","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85 \u2013 01). Radiation Therapy Oncol Group JAMA. 1999;281(17):1623\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1623.","journal-title":"Radiation Therapy Oncol Group JAMA"},{"issue":"24","key":"2808_CR47","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593\u20138. https:\/\/doi.org\/10.1056\/NEJM199206113262403.","journal-title":"N Engl J Med"},{"issue":"8","key":"2808_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/0284186X.2020.1753889","volume":"59","author":"J de Vos-Geelen","year":"2020","unstructured":"de Vos-Geelen J, Hoebers FJP, Geurts SME, et al. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol. 2020;59(8):895\u2013903.","journal-title":"Acta Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02808-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02808-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02808-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:11:08Z","timestamp":1782367868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02808-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2808"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02808-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GS received lecture honoraria and travel expenses from BMS and AstraZeneca. RF received lecture honoraria and\/or travel expenses from IntraOp, Pharmamar and MSD. CP, SJ, HP, JR, KO, KM, PK, RI, SR, SS, SH, VC report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}